Survivin-Based Recombinant Overlapping Peptides Induce T Lymphocyte Cytotoxicity and Prolong the Survival in In Vivo Melanoma Model
Zhang Y. et al, (2023), Advanced Therapeutics, 6
Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker.
Zhou Y. and Jiang S., (2023), Pathogens, 12
Editorial: Peptide-based immunotherapy against emerging viral infections.
Jiang S., (2023), Front Immunol, 14
HIV associated cell death: Peptide-induced apoptosis restricts viral transmission.
Chen Q. et al, (2023), Front Immunol, 14
Editorial: Research, Development and Clinical Trials for Peptide-Based Vaccines.
Jiang S. et al, (2022), Front Immunol, 13
In Vitro and In Vivo Antigen Presentation and Diagnosis Development of Recombinant Overlapping Peptides Corresponding to Mtb ESAT-6/CFP-10.
Zhang Q. et al, (2022), Front Immunol, 13
Survivin as a biological biomarker for diagnosis and therapy.
Li Y. et al, (2021), Expert Opin Biol Ther, 21, 1429 - 1441
Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines.
Stephens AJ. et al, (2021), Front Immunol, 12
TNF-derived peptides inhibit tumour growth and metastasis through cytolytic effects on tumour lymphatics.
Lu W. et al, (2019), Clin Exp Immunol, 198, 198 - 211
ANTIBODY FACILITATING PROGRAMMED NECROSIS OF CELLS AND APPLICATION THEREOF
JIANG S. and Lu W., (2018)
PROTEIN FOR NEUTRALIZING PROGRAMMED NECROCYTOSIS PROMOTION ANTIBODY, AND APPLICATION OF PROTEIN
JIANG S. and Lu W., (2018)
Protective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins.
Cai L. et al, (2017), Oncotarget, 8, 76516 - 76524
Evolutionarily conserved primary TNF sequences relate to its primitive functions in cell death induction.
Lu W. et al, (2016), J Cell Sci, 129, 108 - 120
Immunization with different formulations of Mycobacterium tuberculosis antigen 85A induces immune responses with different specificity and protective efficacy.
Tchilian E. et al, (2013), Vaccine, 31, 4624 - 4631
Immunization with different formulations of Mycobacterium tuberculosis antigen 85A induces immune responses with different specificity and protective efficacy
Tchilian E. et al, (2013), Vaccine, 31, 4624 - 4631

